The awareness for the penny stock of Arch Therapeutics, Inc. (ARTH) has hit a peak (or a desperation point) with dozens of newsletters issuing alerts to end the week. Shares of ARTH stock have had a pretty dismal track record since they peaked at 1.36 just over a month ago. Hoping that surgeons and other doctors, government agencies, hospital and operating room management, ambulances and trauma specialists will one day look to the Company’s AC5™ to better control bleeding and fluid loss, the years needed for this to come to market might be enough to keep investors at bay until the PPS drops another -50%.
Our Next Pick Is Coming Soon! Click HERE To Make Sure You Don’t Miss Any Of Our Breaking Alerts!
ARTH Stock Quote
Market Cap: 29.57M
Last: 0.50 ▲ +0.0400 (+8.70%)
Volume: 377,545
Dollar Volume: $207,494
Open: 0.51
High: 0.52
Low: 0.475
Trades: 100
Authorized: 300,000,000
Issued and Outstanding: 59,145,237
14-Day Rel Strength: 44.51%
1st Resistance Point: 0.5317
1st Support Level: 0.4867
Looking for Hot Penny Stocks?
Click here To Receive FREE Penny Stock Alerts
The market for Arch Therapeutics’ AC5 is large enough to speculate that the day may come when ARTH stock is an attractive buy if the price is right. There are an estimated 114 million surgical and procedure-based wounds which occur annually worldwide, 36 million from surgery in the U.S. alone, according to a report by MedMarket Diligence, LLC in 2012.
However, without any real assets as of June 30, 2013 other than $476,369 of cash and cash equivalents, the lack-luster balance sheet and revenue-less income statement of Arch Therapeutics filed just 2 days ago leaves a lot of room for speculative interpretation.
Since we initiated coverage on ARTH stock back on June 9th, share prices rose quickly from 0.79 to 1.18 before churning until mid-July to peak at 1.36. Since then, ARTH has been on a dilutive path with 3 multi-day bounces which offered gains as large as 82% if timed right.
When it’s all said and done today, ARTH will attract some attention due to the awareness campaigns it has, but, at the end of the day, even gains of 80% on what looks to be headed towards 0.25 just doesn’t seem to be worth the risk.
About ARTH Stock
Arch Therapeutics, Inc. is a medical device company focused on developing polymers containing peptides intended to form gel-like barriers over wounds to stop or control bleeding.
Click here to view the SEC filings for ARTH.
Click here to view the website for Arch Therapeutics.
Last 5 Trading Sessions:
| Date | Last | Change | Volume | |
| 08/15/13 | 0.4600 | -0.0170 | -3.56% | 767,300 |
| 08/14/13 | 0.4770 | +0.0970 | +25.53% | 693,000 |
| 08/13/13 | 0.3800 | -0.0850 | -18.28% | 1,679,500 |
| 08/12/13 | 0.4650 | -0.0350 | -7.00% | 568,000 |
| 08/09/13 | 0.5000 | -0.0300 | -5.66% | 503,600 |
Bottom Line:
Gains are looking unlikely for ARTH today making the penny stocks alerts issued on it as useless as tits on a bull. At half the current price, ARTH stock becomes a bit more attractive, but until the bottom falls out, trading it doesn’t seem to be a prudent exercise.
Stay Connected With Us:
Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter
If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)
ShareAUG
